BRIEF published on 11/13/2024 at 07:05, 1 year 7 months ago SoftwareOne publie une mise à jour de ses résultats commerciaux pour le troisième trimestre 2024 EBITDA Ajusté Croissance Des Revenus Performance Régionale Résultats Du Troisième Trimestre 2024 Modèle GTM
PRESS RELEASE published on 11/13/2024 at 07:00, 1 year 7 months ago SoftwareOne announces Q3 2024 trading update SoftwareOne announces Q3 2024 trading update, with a 3.1% YoY growth in revenue. New leadership aims to restore growth and client centricity. Discussions ongoing for potential going-private transaction Revenue Growth Trading Update SoftwareOne Q3 2024 Going-private
BRIEF published on 10/31/2024 at 07:05, 1 year 7 months ago SoftwareOne Appoints Raphael Erb as CEO and Revises Financial Projections Revenue Growth Financial Guidance CEO Appointment Going-private Transaction SoftwareOne
BRIEF published on 10/31/2024 at 07:05, 1 year 7 months ago SoftwareOne nomme Raphael Erb au poste de PDG et révise ses projections financières Croissance Des Revenus Nomination Du PDG LogicielOne Orientation Financière Transaction De Privatisation
PRESS RELEASE published on 10/31/2024 at 07:00, 1 year 7 months ago SoftwareOne appoints Raphael Erb as CEO; revises financial guidance SoftwareOne appoints Raphael Erb as new CEO, revises financial guidance. Q3 2024 results below expectations; ongoing going-private discussions Financial Guidance SoftwareOne CEO Raphael Erb Going-private
BRIEF published on 08/21/2024 at 17:50, 1 year 10 months ago SoftwareOne Delivers Solid H1 2024 Results Amid Economic Uncertainty Revenue Growth EBITDA Margin SoftwareOne Vision 2026 H1 2024 Results
BRIEF published on 08/21/2024 at 17:50, 1 year 10 months ago SoftwareOne publie de solides résultats au premier semestre 2024 dans un contexte d'incertitude économique Vision 2026 Croissance Des Revenus Marge D'EBITDA LogicielOne Résultats Du 1er Semestre 2024
PRESS RELEASE published on 08/21/2024 at 17:45, 1 year 10 months ago SoftwareOne delivers solid results in H1 2024, with implementation of Vision 2026 on track SoftwareOne announces solid results in H1 2024, with Vision 2026 implementation on track. Revenue up 7.0% YoY, adjusted EBITDA up 11.3% Adjusted EBITDA Revenue Growth SoftwareOne Vision 2026 H1 2024
BRIEF published on 08/21/2024 at 07:05, 1 year 10 months ago SoftwareOne Reports Solid H1 2024 Results, Keeps Vision 2026 On Track EBITDA Margin SoftwareOne Vision 2026 H1 2024 Results Copilot 365
BRIEF published on 08/21/2024 at 07:05, 1 year 10 months ago SoftwareOne publie de solides résultats pour le premier semestre 2024 et maintient son objectif Vision 2026 sur la bonne voie Vision 2026 Marge D'EBITDA LogicielOne Résultats Du 1er Semestre 2024 Copilote 365
Published on 06/26/2026 at 14:05, 2 hours 56 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 1 minute ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 1 minute ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 16 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 1 hour 30 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
